Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Department of Dermatology Augsburg, Hauttumorzentrum, Augsburg.
Hans
H
Starz
Manuela
M
Gutschi
Julia
J
Welzel
Christian
C
Haas
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D009154:Mutation / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D013449:Sulfonamides / Q000627:therapeutic use*; D013899:Thoracic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary; D017211:Treatment Failure; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf